Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 2:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,154 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Influenza Vaccine Clear all
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)

NCT07128615
View directory record Official record
Conditions
Influenza A
Interventions
AZD4117, AZD5315, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
14
States / cities
Long Beach, California • Rolling Hills Estates, California • Hialeah, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 9, 2026, 2:35 AM EDT
Withdrawn No phase listed Observational

2009 H1N1 Pandemic and Seasonal Influenza in SCI/D: Infection Control Strategies

NCT01270685
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 9, 2026, 2:35 AM EDT
Completed Phase 2 Interventional

A Clinical Trial of KT07 Capsule in the U.S.A

NCT02867358
View directory record Official record
Conditions
Influenza, Human
Interventions
KT07 Capsule, Placebo
Drug · Other
Lead sponsor
Yiling Pharmaceutical Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
81
States / cities
Birmingham, Alabama • Pelham, Alabama • Tolleson, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 9, 2026, 2:35 AM EDT
Completed Not applicable Interventional

Effectiveness of Influenza Vaccine Reminder Systems

NCT01852656
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease
Interventions
Postcard and IVR Reminder Group, Postcard Only Reminder Group, IVR Only Reminder Group
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
19 Years to 64 Years
Enrollment
12,255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 9, 2026, 2:35 AM EDT
Completed Phase 2 Interventional

Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects

NCT00979251
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir Phosphate, ADS-8902
Drug
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
San Francisco, California • Hollywood, Florida • Miramar, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 9, 2026, 2:35 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older

NCT00741039
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Prostate Cancer
Interventions
inactivated influenza vaccine and the 23- valent pneumococcal vaccine, inactivated influenza vaccine and the PPV23 vaccine (Pneumovax)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
65 Years and older
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 9, 2026, 2:35 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively

NCT04109222
View directory record Official record
Conditions
Influenza
Interventions
Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation, Fluzone High-Dose vaccine, 2019-2020 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 83 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 9, 2026, 2:35 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo

NCT06435936
View directory record Official record
Conditions
PHA1A
Interventions
Single Ascending Dose of SAB-176, Single Ascending Dose of Placebo
Drug
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 9, 2026, 2:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents

NCT01609998
View directory record Official record
Conditions
Influenza
Interventions
Seasonal Influenza DNA vaccine, TIV
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 17 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
Atlanta, Georgia • St Louis, Missouri • Lebanon, New Hampshire + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 9, 2026, 2:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of the Immune Response After Vaccination in Multiple Myeloma Patients

NCT02294487
View directory record Official record
Conditions
Multiple Myeloma, Myeloma, Multiple, Myeloma-Multiple
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 9, 2026, 2:35 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults

NCT02563093
View directory record Official record
Conditions
Influenza
Interventions
Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative, Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation, Fluzone High-Dose vaccine, 2015-2016 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
4
States / cities
Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Oct 9, 2026, 2:35 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Jet Injection for Influenza

NCT01688921
View directory record Official record
Conditions
Influenza, Human
Interventions
AFLURIA vaccine (2012-2013 formulation), Needle-Syringe, Stratis needle-free injection device
Biological · Device
Lead sponsor
PharmaJet, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
3
States / cities
Fort Collins, Colorado • Loveland, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 1, 2017 · Synced Oct 9, 2026, 2:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Elderly Influenza Vaccine Immunogenicity Substudy

NCT00170482
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Oct 9, 2026, 2:35 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Response to Inactivated Influenza Vaccine in Lymph Tissue and Blood

NCT03898973
View directory record Official record
Conditions
Influenza
Interventions
Quadrivalent inactivated influenza vaccine (IIV)
Biological
Lead sponsor
Stanford University
Other
Eligibility
20 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Oct 9, 2026, 2:35 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immune and Hormone Response to Influenza Vaccine

NCT01978262
View directory record Official record
Conditions
Healthy
Interventions
Seasonal Inactivated Influenza Vaccine
Biological
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 27, 2018 · Synced Oct 9, 2026, 2:35 AM EDT
Completed Phase 3 Interventional Results available

Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza

NCT02635724
View directory record Official record
Conditions
Influenza
Interventions
Peramivir
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Brooksville, Florida • Lakeland, Florida • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 9, 2026, 2:35 AM EDT
Enrolling by invitation Not applicable Interventional

Patient-Centered Practical Vaccine Talk For Busy Clinicians

NCT07651761
View directory record Official record
Conditions
Influenza, COVID-19
Interventions
Provider communication training
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
24,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 9, 2026, 2:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days

NCT00989404
View directory record Official record
Conditions
Influenza A Virus, H1N1 Subtype
Interventions
Zanamivir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 9, 2026, 2:35 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Open-Label Study of H5 Vaccine in Participants of Protocol 04-077

NCT00402649
View directory record Official record
Conditions
Influenza
Interventions
Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 10 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
3
States / cities
Torrance, California • Baltimore, Maryland • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Oct 9, 2026, 2:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Immune Responses to the Flu Shot During Pregnancy

NCT02148874
View directory record Official record
Conditions
Pregnancy
Interventions
influenza virus vaccination
Biological
Lead sponsor
Lisa Christian
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
287 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 9, 2026, 2:35 AM EDT
Terminated Phase 4 Interventional Results available

Test-and-treat for Influenza in Homeless Shelters

NCT04141917
View directory record Official record
Conditions
Influenza, Respiratory Viral Infection
Interventions
Point-of-care molecular testing and treatment of influenza
Combination Product
Lead sponsor
University of Washington
Other
Eligibility
3 Months and older
Enrollment
1,618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Burien, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 9, 2026, 2:35 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children

NCT06038617
View directory record Official record
Conditions
Fever After Vaccination, Fever, Seizures Fever
Interventions
mRNA COVID-19 Vaccine, Routine Childhood Vaccinations
Biological
Lead sponsor
Duke University
Other
Eligibility
6 Months to 4 Years
Enrollment
347 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
5
States / cities
Oakland, California • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 9, 2026, 2:35 AM EDT
Completed Not applicable Interventional Results available

Patient Portal Reminder/Recall for Influenza Vaccination in a Health System- UCLA Portal R/R Influenza RCT 3

NCT04533685
View directory record Official record
Conditions
Influenza, Respiratory Tract Infections
Interventions
Portal Reminders for Influenza Vaccination: Direct scheduling link, Portal Reminders for Influenza Vaccination: No direct scheduling link, Pre-Commitment Prompt, Pre-Appointment flu vaccine reminders
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
4 Months and older
Enrollment
213,773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 9, 2026, 2:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults

NCT00603811
View directory record Official record
Conditions
Influenza Infection
Interventions
VAX102 [Flagellin.HuM2e], Placebo
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Lenexa, Kansas • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2014 · Synced Oct 9, 2026, 2:35 AM EDT